MA-RENAGADE-THERAPEUTICS
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
“We are excited to highlight foundational research and development advancements at ASGCT supported by our poster presentation illuminating ReNAgade’s continued work in validating our immune tropic LNP-based delivery systems in NHPs with broad potential applications in oncology and autoimmune diseases,” said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. “Additionally, our oral presentation demonstrates a non-viral, all-RNA gene editing system enabling in vivo, exon-sized insertion and probable re-dosing with the goal of higher specificity and a better safety profile when used in the clinical setting. Together, these promising data are another important step in our efforts to innovate beyond the current limitations of RNA medicine.”
Key Highlights from the Abstracts:
- Employed a systematic barcoding screening approach to evaluate and identify engineered lipid nanoparticles (LNP) from a library of 200+ LNPs across multiple structural and chemically distinct classes of ionizable, helper, structural, and hydrophilic lipids. Lead LNP candidate demonstrated ~60% delivery efficiency in total splenic T cells and ~80% delivery efficiency in peripheral blood T cells in non-human primate models.
- Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation. Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.
ASGCT Annual Meeting Presentation Details:
- TITLE: “Retron Mediated Exon-Sized Genome Insertion Using an All-RNA System”
SESSION TITLE: New Technologies for Gene Targeting and Gene Correction
PRESENTATION TYPE: Oral
ABSTRACT NUMBER: 14
PRESENTER: Inna Shcherbakova, Ph.D., Senior Director, Platform, ReNAgade Therapeutics
DATE AND TIME: Tuesday, May 7, 2024, from 2:15 p.m. - 3:30 p.m. ET
- TITLE: “Novel Immune Tropic LNP-Based mRNA Delivery in Non-Human Primates”
SESSION TITLE: Wednesday Posters: Other Nonviral Delivery
PRESENTATION TYPE: Poster
ABSTRACT NUMBER: 749
PRESENTER: Juliet Crabtree, Ph.D., Associate Principal Scientist, ReNAgade Therapeutics
DATE AND TIME: Wednesday, May 8, 2024, at 12:00 p.m. ET
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422868550/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership11.12.2024 14:30:00 CET | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has been honored with the 2024 Fierce CRO Award for Excellence in Client Service and Partnership. This prestigious award recognizes Crown Bioscience's outstanding collaboration, communication, and commitment to delivering excellence for its life sciences clients. The Fierce CRO Awards, hosted annually by Fierce Biotech, celebrate the achievements of leading CROs that demonstrate innovation and leadership in accelerating drug development. Winners in this category are selected based on their commitment to building strong partnerships and providing an exceptional client experience. "Winning this award is a true testament to our team’s dedication to going above and beyond for our clients," said Dr. Jonny McMichael, Vice President of Client Experience and Enablement at Crown Bioscience. "We aim to accelerate the journey of new th
Planforge Launches Broad Initiative for AI-Powered Project Work Management11.12.2024 14:30:00 CET | Press release
Development Focuses on Practical Use Cases Based on Comprehensive Research and Collaborative Customer Feedback AI is transforming the world of project management by offering solutions to complex problems. Yet, many project managers struggle to pinpoint AI applications that deliver tangible, practical value. Planforge, a leading provider of project work management software, is precisely addressing this challenge head-on. The company’s new AI initiative focuses on identifying and developing features that offer practical support to project managers, specifically designed for standards-based project management in Europe. The first use cases are set to debut in the upcoming 2025 release, featuring AI-driven enhancements aimed at streamlining project planning processes and enabling managers to define clear objectives more efficiently. This initiative marks the beginning of Planforge’s long-term commitment to advancing AI-powered solutions for project management. In-Depth Research and Real-Wo
SLB Awarded Integrated Services Contract for All Petrobras’ Offshore Fields in Brazil11.12.2024 14:22:00 CET | Press release
Following a competitive tender process, the award covers more than 100 wells across nine ultra-deepwater rigs including exploratory and revitalization wells in the Campos Basin, with potential operations in the Equatorial Margin Global energy technology company SLB (NYSE: SLB) today announced that it has been awarded, after a competitive tender, a new contract by Petrobras (NYSE: PBR) for integrated services across all offshore fields operated by Petrobras in Brazil. SLB will oversee the construction of more than 100 deepwater wells, utilizing advanced drilling, cementing and drilling fluids technologies on up to nine ultra-deepwater rigs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211656672/en/ Technologies to be deployed under the contract include transition technologies such as SLB’s Ora™ intelligent wireline formation testing platform and SpectraSphere™ fluid mapping-while-drilling service. (Photo: Business Wire)
The Board of Verne Appoints Data Center Industry Veteran A. William Stein as Non-Executive Chairman11.12.2024 14:00:00 CET | Press release
Following recent acquisition by Ardian, former CEO of Digital Realty joins Verne board to accelerate growth and guide the company’s Nordic expansion as it continues to build out its sustainably powered data center platform Verne, the leading provider of sustainably powered HPC data centers across the Nordics, and Ardian, a world-leading private investment house, today announced that A. William “Bill” Stein, former CEO of Digital Realty Trust, has been appointed as Chair of Verne’s board of directors as it continues to build out its sustainably-powered data center platform. Bill Stein's appointment reflects his extensive background in corporate growth, strategic investment, and operational excellence, making him an invaluable asset to Verne's long-term growth strategy and vision for the data center industry. The appointment comes ten months after Ardian acquired Verne. With more than three decades of executive leadership experience spanning diverse industries and roles, Stein currently
Cyclic Materials Secures Multi-Year Agreement to Supply Recycled Copper to Global Natural Resources Company Glencore11.12.2024 14:00:00 CET | Press release
Cyclic Materials will supply copper from its Spoke operations to Glencore’s copper recycling operation in Quebec, Canada Cyclic Materials, an advanced metals recycling company building a circular supply chain for rare earth elements (REEs) and other critical metals, today announced the signing of a multi-year offtake agreement with Glencore, a global natural resources company, for the supply of copper produced at its Spoke operations. The strategic partnership aims to advance sustainable practices in the rare earths industry and drive copper circularity while addressing the growing demand for securing recycled materials central to the energy transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211238738/en/ Cyclic Materials will provide Glencore with high-quality copper extracted and processed from electric motors that will be reutilized in new end-products. This strategic partnership is driving copper circularity a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom